Proteomic technologies provide the means to define and compare protein profiles in normal and pathological samples, correlate protein profiles with biological activities, define disease mechanisms at a molecular level, establish interrelationships among proteins, identify temporal patterns of expression, and define the function of uncharacterized proteins. As a result, there is intense interest in applying proteomics to foster a better understanding of cancer processes, develop new biomarkers for diagnosis, early detection, prediction and prognosis of cancer, identify tumor antigens recognized by the immune system, discover new molecular targets for accelerated drug development and identify markers for therapeutic efficacy, toxicity and patient stratification
The mission of the DF/HCC Cancer Proteomics Core is to develop a comprehensive and interdisciplinary proteomics core for High Sensitivity, High Resolution and High Throughput Proteomics as a new DF/HCC core with particular emphasis on in depth proteomic consultation, referral to the optimal proteomics facility and a strong focus on clinical sample analysis. This facility will provide access to all DF/HCC researchers and will evolve as the central proteomics gateway for DF/HCC investigators. A close coordination with other Harvard proteomics facilities will ensure the optimal proteomic service for each individual DF/HCC investigator.
The Core provides high sensitivity and high resolution proteomics technologies essential for many DF/HCC researchers to stay competitive and at the cutting edge of science and will provide a wealth of novel data that are otherwise not obtainable and that guarantee future, new grant awards.